Jinghui Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinghui Liang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hui Tian
Shandong Key Laboratory of Digital Diagnosis and Treatment of Thoracic Oncology, Shandong Engineering Research Center of Intelligent Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China
31 shared publications - Jin Jiang
Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China
31 shared publications - Jingyi Han
Department of Thoracic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong Key Laboratory of Targeted Drug Delivery and Advanced Pharmaceutics, NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
31 shared publications - Renchang Zhao
Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China
31 shared publications - Rongyang Li
Department of Thoracic Surgery Qilu Hospital of Shandong University Jinan Shandong China
31 shared publications - Tao Fang
Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China
31 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from EIF4A3 Acts on the PI3K–AKT–ERK1/2–P70S6K Pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma
EIF4A3 promotes the proliferation and migration of LUAD cells in vitro.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from EIF4A3 Acts on the PI3K–AKT–ERK1/2–P70S6K Pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma
EIF4A3 promotes the proliferation and migration of LUAD cells in vitro.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from EIF4A3 Acts on the PI3K–AKT–ERK1/2–P70S6K Pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma
Correlation between EIF4A3 expression and clinicopathological characteristics in LUAD
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from EIF4A3 Acts on the PI3K–AKT–ERK1/2–P70S6K Pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma
Correlation between EIF4A3 expression and clinicopathological characteristics in LUAD
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from EIF4A3 Acts on the PI3K–AKT–ERK1/2–P70S6K Pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma
Sequence of small interfering RNA
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from EIF4A3 Acts on the PI3K–AKT–ERK1/2–P70S6K Pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma
Sequence of small interfering RNA
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
Correlation between EIF4A3 expression and clinicopathological characteristics in LUAD
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
Correlation between EIF4A3 expression and clinicopathological characteristics in LUAD
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
EIF4A3 promotes the proliferation and migration of LUAD cells in vitro.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
EIF4A3 promotes the proliferation and migration of LUAD cells in vitro.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
Lung adenocarcinoma (LUAD) is a major lung cancer subtype. In this study, we discovered that the eukaryotic translation initiation factor EIF4A3 expression was significantly higher in LUAD tissues, and that this higher expression was closely linked to a poor prognosis for LUAD. In addition, we demonstrated that the knockdown of EIF4A3 significantly inhibited the proliferation, invasion, and migration of LUAD cells in vitro and in vivo. The findings of mass spectrometry analysis revealed that EIF4A3 could interact with Flotillin-1 in lung adenocarcinoma cells and that EIF4A3 could positively regulate the expression of FLOT1 at the protein level. Meanwhile, transcriptome sequencing showed that EIF4A3 could influence the development of lung adenocarcinoma by affecting PI3K-AKT-ERK1/2-P70S6K and PI3K class III-mediated autophagy in the Apelin pathway. In addition, we confirmed that Flotillin-1 expression was upregulated in LUAD based on the existing literature, and knockdown of FLOT1 could inhibit the proliferation and migration of LUAD cells. And the knockdown of Flotillin-1 reversed the increase of cell proliferation and migration caused by EIF4A3 overexpression. Furthermore, we found that the activation of PI3K-AKT-ERK1/2-P70S6K signaling pathway and PI3K class III-mediated autophagy caused by EIF4A3 overexpression was rescued by the knockdown of FLOT1. In a word, we proved that EIF4A3 positively regulates the expression of FLOT1 and plays a pro-cancer role in LUAD. Implications: Our study revealed the role of EIF4A3 in prognosis and tumor progression in LUAD, indicating that EIF4A3 could be employed as the molecular diagnostic and prognostic therapeutic target.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
Lung adenocarcinoma (LUAD) is a major lung cancer subtype. In this study, we discovered that the eukaryotic translation initiation factor EIF4A3 expression was significantly higher in LUAD tissues, and that this higher expression was closely linked to a poor prognosis for LUAD. In addition, we demonstrated that the knockdown of EIF4A3 significantly inhibited the proliferation, invasion, and migration of LUAD cells in vitro and in vivo. The findings of mass spectrometry analysis revealed that EIF4A3 could interact with Flotillin-1 in lung adenocarcinoma cells and that EIF4A3 could positively regulate the expression of FLOT1 at the protein level. Meanwhile, transcriptome sequencing showed that EIF4A3 could influence the development of lung adenocarcinoma by affecting PI3K-AKT-ERK1/2-P70S6K and PI3K class III-mediated autophagy in the Apelin pathway. In addition, we confirmed that Flotillin-1 expression was upregulated in LUAD based on the existing literature, and knockdown of FLOT1 could inhibit the proliferation and migration of LUAD cells. And the knockdown of Flotillin-1 reversed the increase of cell proliferation and migration caused by EIF4A3 overexpression. Furthermore, we found that the activation of PI3K-AKT-ERK1/2-P70S6K signaling pathway and PI3K class III-mediated autophagy caused by EIF4A3 overexpression was rescued by the knockdown of FLOT1. In a word, we proved that EIF4A3 positively regulates the expression of FLOT1 and plays a pro-cancer role in LUAD. Implications: Our study revealed the role of EIF4A3 in prognosis and tumor progression in LUAD, indicating that EIF4A3 could be employed as the molecular diagnostic and prognostic therapeutic target.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
Sequence of small interfering RNA
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
Sequence of small interfering RNA
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
Sequence of small interfering RNA
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to influence the development of lung adenocarcinoma
Sequence of small interfering RNA